keyword
MENU ▼
Read by QxMD icon Read
search

Geodon

keyword
https://www.readbyqxmd.com/read/27703782/ketamine-stimulating-antidepressant-treatment
#1
Gin S Malhi, Yulisha Byrow, Frederick Cassidy, Andrea Cipriani, Koen Demyttenaere, Mark A Frye, Michael Gitlin, Sidney H Kennedy, Terence A Ketter, Raymond W Lam, Rupert McShane, Alex J Mitchell, Michael J Ostacher, Sakina J Rizvi, Michael E Thase, Mauricio Tohen
SUMMARY: The appeal of ketamine - in promptly ameliorating depressive symptoms even in those with non-response - has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to ketamine's potential as an option for treating depression and provide a synthesis of perspectives - derived from evidence and clinical experience - and to consider strategies for future investigations...
May 2016: BJPsych Open
https://www.readbyqxmd.com/read/23599678/cardiometabolic-consequences-of-therapy-for-chronic-schizophrenia-using-second-generation-antipsychotic-agents-in-a-medicaid-population-clinical-and-economic-evaluation
#2
Alex Ward, Peter Quon, Safiya Abouzaid, Noah Haber, Saed Ahmed, Edward Kim
OBJECTIVE: We assessed the potential clinical and economic impact of coronary heart disease (CHD) and diabetes arising after the use of second-generation ("atypical") antipsychotic agents for the treatment of chronic schizophrenia. We compared the use of these medications in patients with a higher risk of cardiometabolic adverse events (in a higher-risk scenario) and in patients with a lower risk (in a lower-risk scenario). Our U.S.-based analysis estimated the costs of CHD and diabetes arising from antipsychotic medication-related cardiometabolic effects...
February 2013: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/22477804/stability-of-ziprasidone-mesylate-in-an-extemporaneously-compounded-oral-solution
#3
Kelsey Green, Roy C Parish
OBJECTIVES: To formulate a liquid preparation of ziprasidone in a convenient concentration to allow dosing of less than 20 mg and of sufficient chemical and physical stability to enable an entire prescription or course of treatment to be prepared in a single batch. METHODS: Geodon for injection (ziprasidone mesylate), 20 mg/mL, was diluted to 2.5 mg/mL in a commercially available sugar-free and alcohol-free, flavored syrup and stored at room temperature under ambient fluorescent light illumination, at room temperature in darkness, and under refrigeration...
April 2010: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://www.readbyqxmd.com/read/22349051/in-vitro-and-in-vivo-characterization-of-amorphous-nanocrystalline-and-crystalline-ziprasidone-formulations
#4
Avinash G Thombre, Jaymin C Shah, Kazuko Sagawa, W Brett Caldwell
Ziprasidone, commercially available as Geodon capsules, is an atypical antipsychotic used in the treatment of schizophrenia and bipolar disorder. It is a BCS Class II drug that shows up to a 2-fold increase in absorption in the presence of food. Because compliance is a major issue in this patient population, we developed and characterized solubilized formulations of ziprasidone in an effort to improve absorption in the fasted state, thereby resulting in a reduced food effect. Three formulations utilizing solubilization technologies were studied: (1) an amorphous inclusion complex of ziprasidone mesylate and a cyclodextrin, (2) a nanosuspension of crystalline ziprasidone free base, and (3) jet-milled ziprasidone HCl coated crystals made by spray drying (CCSD) the drug with hypromellose acetate succinate...
May 30, 2012: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/21674263/improved-ziprasidone-formulations-with-enhanced-bioavailability-in-the-fasted-state-and-a-reduced-food-effect
#5
Avinash G Thombre, Scott M Herbig, Jeffrey A Alderman
PURPOSE: To develop and characterize new formulations of ziprasidone with a reduced food effect achieved by increasing exposure in the fasted state. METHODS: Formulations were developed utilizing the following solubilization technologies: inclusion complex of ziprasidone mesylate and cyclodextrin, ziprasidone free base nano-suspension, and semi-ordered ziprasidone HCl in polymer matrix. Pharmacokinetic studies were conducted with these formulations to examine the bioavailability of test formulations in fasted and fed state compared to commercial capsules (GeodonĀ®) dosed in the fed state...
December 2011: Pharmaceutical Research
https://www.readbyqxmd.com/read/19192477/a-meta-analysis-of-the-risk-of-acute-extrapyramidal-symptoms-with-intramuscular-antipsychotics-for-the-treatment-of-agitation
#6
COMPARATIVE STUDY
Theodore D Satterthwaite, Daniel H Wolf, Robert A Rosenheck, Raquel E Gur, Stanley N Caroff
OBJECTIVE: We examined the evidence for a decreased risk of extrapyramidal symptoms (EPS) with intramuscular second-generation antipsychotics (SGAs) versus intramuscular haloperidol alone or in combination with an anticholinergic agent. DATA SOURCES: We searched MEDLINE (1950 to the present), and EMBASE and the Cochrane Database through January 16, 2008, for studies published in English of intramuscular SGAs and intramuscular haloperidol alone or in combination with an anticholinergic agent using the following drug names: ziprasidone, Geodon, olanzapine, Zyprexa, aripiprazole, Abilify, haloperidol, and Haldol...
December 2008: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/18606348/profound-hypothermia-secondary-to-normal-ziprasidone-use
#7
Gregory M Gibbons, David A Wein, Richard Paula
Clinically significant hypothermia is a commonly evaluated condition in emergency medicine. Most cases are related to prolonged exposure to the environment, infection, or endocrinopathies. Presented here is a case of hypothermia likely induced by an atypical antipsychotic medication. A 69-year-old incarcerated man presented to our emergency department with an oral temperature of 85 degrees F (29.4 degrees C). The patient was taking ziprasidone (Geodon, Pfizer, New York, NY) 80 mg twice daily. Atypical antipsychotic medications have been implicated in numerous cases of clinically significant hypothermia...
July 2008: American Journal of Emergency Medicine
https://www.readbyqxmd.com/read/17140281/ziprasidone-a-review-of-its-use-in-schizophrenia-and-schizoaffective-disorder
#8
REVIEW
Tracy Swainston Harrison, Lesley J Scott
Ziprasidone (Geodon, Zeldox) is an atypical antipsychotic agent with a unique neurotransmitter receptor-binding profile. The oral formulation is indicated for the treatment of adult patients with schizophrenia and the intramuscular formulation for the control of acute agitation in these patients. In adult patients with schizophrenia or schizoaffective disorder, oral ziprasidone was effective at a dosage of 40-80 mg twice daily in patients experiencing a phase of acute illness, and at a dosage of 20-80 mg twice daily in those with chronic schizophrenia or schizoaffective disorder, including those who were symptomatically stable...
2006: CNS Drugs
https://www.readbyqxmd.com/read/16278769/ziprasidone-mesylate-geodon-for-injection-the-first-injectable-atypical-antipsychotic-medication
#9
Valerie Sheehan
No abstract text is available yet for this article.
October 2003: Proceedings of the Baylor University Medical Center
https://www.readbyqxmd.com/read/16247923/best-clinical-practice-with-ziprasidone-im-update-after-2-years-of-experience
#10
REVIEW
Dan L Zimbroff, Michael H Allen, John Battaglia, Leslie Citrome, Avrim Fishkind, Andrew Francis, Daniel L Herr, Douglas Hughes, Marc Martel, Horacio Preval, Ruth Ross
Acute agitation is a common psychiatric emergency often treated with intramuscular (i.m.) medication when rapid control is necessary or the patient refuses to take an oral agent. Conventional i.m. antipsychotics are associated with side effects, particularly movement disorders, that may alarm patients and render them unreceptive to taking these medications again. Ziprasidone (Geodon) is the first second-generation, or atypical, antipsychotic to become available in an i.m. formulation. Ziprasidone IM was approved by the Food and Drug Administration in 2002 for the treatment of agitation in patients with schizophrenia...
September 2005: CNS Spectrums
https://www.readbyqxmd.com/read/15869022/atypical-antipsychotic-therapy-and-hyperlipidemia-a-review
#11
REVIEW
Carol E Koro, Jonathan M Meyer
Ziprasidone (Geodon), risperidone (Risperdal), and aripiprazole (Abilify) appear to be associated with a relatively low risk for hyperlipidemia, whereas quetiapine (Seroquel), olanzapine (Zyprexa), and clozapine (Clozaril) are associated with a relatively high risk for hyperlipidemia. Possible underlying causes of lipid dysregulation include weight gain, dietary changes, and glucose intolerance. Given the multiple cardiovascular risk factors reported for patients with schizophrenia, great care must be exercised to minimize the additional risk for hyperlipidemia when choosing antipsychotic therapy...
2005: Essential Psychopharmacology
https://www.readbyqxmd.com/read/15853589/pharmacological-treatment-strategies-for-schizophrenia
#12
REVIEW
J P Lindenmayer, Anzalee Khan
The pharmacological choices for the treatment of schizophrenia have been greatly expanded with the availability of the atypical compounds clozapine (Clozaril, Novartis), risperidone (Risperdal, Janssen-Cilag), olanzapine (Zyprexa, Eli Lilly & Co.), quetiapine (Seroquel, AstraZeneca), ziprasidone (Geodon, Pfizer Inc.) and aripiprazole (Abilify, Otsuka Pharmaceutical Co. Ltd). In this article, the effects of the newer antipsychotics and their side effects are reviewed. Key issues in acute and maintenance treatment, often lifelong, will be reviewed...
July 2004: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/15853558/ziprasidone-a-novel-psychotropic-with-unique-properties
#13
REVIEW
Christos Ballas, Calvin Yang, John O'Reardon, Paul Ballas, Claudia Baldassano
Ziprasidone (Geodon) is a relatively new atypical antipsychotic medication with a unique pharmacological profile. It is indicated for the treatment of schizophrenia, but has also often been used off-label for other uses. This review summarizes its important properties, specifically the pharmacodynamic parameters, receptor-binding profile and relevance to clinical outcomes, side effects, and potential for drug-drug interactions and established clinical indications. Novel therapeutic applications and relevant clinical trials or reports are also examined...
March 2004: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/15821046/characterization-of-a-novel-metabolite-intermediate-of-ziprasidone-in-hepatic-cytosolic-fractions-of-rat-dog-and-human-by-esi-ms-ms-hydrogen-deuterium-exchange-and-chemical-derivatization
#14
Zhuang Miao, Amin Kamel, Chandra Prakash
Ziprasidone (Geodone), a novel atypical antipsychotic agent, is recently approved for the treatment of schizophrenia. It undergoes extensive metabolism in preclinical species and humans after oral administration, and only a very small amount of administered dose is excreted as unchanged drug. In vitro studies using human liver microsomes have shown that the oxidative metabolism of ziprasidone is mediated primarily by CYP3A4. However, coadministration of ziprasidone with ketoconazole, a CYP3A4 inhibitor, showed only a modest increase in its exposure...
July 2005: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/12826984/ziprasidone-metabolism-aldehyde-oxidase-and-clinical-implications
#15
REVIEW
Christine Beedham, Jeffrey J Miceli, R Scott Obach
Ziprasidone (Geodon, Zeldox), a recently approved atypical antipsychotic agent for the treatment of schizophrenia, undergoes extensive metabolism in humans with very little (<5%) of the dose excreted as unchanged drug. Two enzyme systems have been implicated in ziprasidone metabolism: the cytosolic enzyme, aldehyde oxidase, catalyzes the predominant reductive pathway, and cytochrome P4503A4 (CYP3A4) is responsible for two alternative oxidation pathways. The involvement of two competing pathways in ziprasidone metabolism greatly reduces the potential for pharmacokinetic interactions between ziprasidone and other drugs...
June 2003: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/12645973/cardiotoxicity-associated-with-intentional-ziprasidone-and-bupropion-overdose
#16
Abhik K Biswas, Luke A Zabrocki, Kendra L Mayes, Cynthia L Morris-Kukoski
BACKGROUND: Ziprasidone (Geodon) and bupropion (Wellbutrin) are medications prescribed for mood and behavior disorders. They have apparently safe cardiac safety profiles in both therapeutic and supra-therapeutic doses. CASE REPORT: A 17-year-old male developed a widened QRS and a prolonged QTc interval following an overdose of ziprasidone and bupropion. He required hospital admission for aggressive cardiac monitoring and antidysrhythmic therapy, stabilizing to baseline by 80 hours post-ingestion...
2003: Journal of Toxicology. Clinical Toxicology
https://www.readbyqxmd.com/read/11825308/ziprasidone-profile-on-safety
#17
REVIEW
P J Goodnick
Ziprasidone (Geodon, Pfizer) is the latest of a new class of atypical antipsychotics, following the release of clozapine, risperidone, olanzapine and quetiapine. It has a serotonin Type 2a/dopamine Type 2 (5-HT2a/D2) receptor (R) binding ratio of approximately 8:1; amongst the highest of its class. Furthermore, it is a potent 5-HT1aR agonist, and displays 5-HT1dR and 5-HT2cR antagonist activity, with unique effects on blocking the re-uptake of both 5-HT and noradrenaline (NE). Finally, ziprasidone has low-to-modest affinity for histamine (H1) and alpha 1-adrenoceptors and a negligible affinity for muscarinic (M1) Rs...
October 2001: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/11402259/ziprasidone-geodon-for-schizophrenia
#18
(no author information available yet)
No abstract text is available yet for this article.
June 11, 2001: Medical Letter on Drugs and Therapeutics
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"